Literature DB >> 33798473

Redirecting macrophage function to sustain their "defender" antitumor activity.

Stephanie L Tzetzo1, Scott I Abrams2.   

Abstract

Macrophages are multi-functional innate immune cells that occupy normal or pathologic tissues, including cancer tissues. The importance of macrophage ontogeny and the transcriptional networks underlying their functional diversity are underappreciated in immuno-oncology. Here, we discuss the implications of these fundamental characteristics for therapeutically reprogramming macrophages to sustain their tumoricidal activities.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2021        PMID： 33798473      PMCID： PMC8852249          DOI： 10.1016/j.ccell.2021.03.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   38.585


  15 in total

Review 1.  Macrophages: The Road Less Traveled, Changing Anticancer Therapy.

Authors:  Jennifer L Guerriero
Journal:  Trends Mol Med       Date:  2018-04-11       Impact factor: 11.951

2.  Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression.

Authors:  Yu Zhu; John M Herndon; Dorothy K Sojka; Ki-Wook Kim; Brett L Knolhoff; Chong Zuo; Darren R Cullinan; Jingqin Luo; Audrey R Bearden; Kory J Lavine; Wayne M Yokoyama; William G Hawkins; Ryan C Fields; Gwendalyn J Randolph; David G DeNardo
Journal:  Immunity       Date:  2017-08-15       Impact factor: 31.745

3.  Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies.

Authors:  Robert L Bowman; Florian Klemm; Leila Akkari; Stephanie M Pyonteck; Lisa Sevenich; Daniela F Quail; Surajit Dhara; Kenishana Simpson; Eric E Gardner; Christine A Iacobuzio-Donahue; Cameron W Brennan; Viviane Tabar; Philip H Gutin; Johanna A Joyce
Journal:  Cell Rep       Date:  2016-11-10       Impact factor: 9.423

4.  Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival.

Authors:  C M Ohri; A Shikotra; R H Green; D A Waller; P Bradding
Journal:  Eur Respir J       Date:  2009-01       Impact factor: 16.671

5.  RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.

Authors:  Wei Wang; Jill M Marinis; Allison M Beal; Shivraj Savadkar; Yue Wu; Mohammed Khan; Pardeep S Taunk; Nan Wu; Wenyu Su; Jingjing Wu; Aarif Ahsan; Emma Kurz; Ting Chen; Inedouye Yaboh; Fei Li; Johana Gutierrez; Brian Diskin; Mautin Hundeyin; Michael Reilly; John D Lich; Philip A Harris; Mukesh K Mahajan; James H Thorpe; Pamela Nassau; Julie E Mosley; Joshua Leinwand; Juan A Kochen Rossi; Ankita Mishra; Berk Aykut; Michael Glacken; Atsuo Ochi; Narendra Verma; Jacqueline I Kim; Varshini Vasudevaraja; Dennis Adeegbe; Christina Almonte; Ece Bagdatlioglu; Deirdre J Cohen; Kwok-Kin Wong; John Bertin; George Miller
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

6.  PI3Kγ is a molecular switch that controls immune suppression.

Authors:  Megan M Kaneda; Karen S Messer; Natacha Ralainirina; Hongying Li; Christopher J Leem; Sara Gorjestani; Gyunghwi Woo; Abraham V Nguyen; Camila C Figueiredo; Philippe Foubert; Michael C Schmid; Melissa Pink; David G Winkler; Matthew Rausch; Vito J Palombella; Jeffery Kutok; Karen McGovern; Kelly A Frazer; Xuefeng Wu; Michael Karin; Roman Sasik; Ezra E W Cohen; Judith A Varner
Journal:  Nature       Date:  2016-09-19       Impact factor: 49.962

7.  TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.

Authors:  Christopher B Rodell; Sean P Arlauckas; Michael F Cuccarese; Christopher S Garris; Ran Li; Maaz S Ahmed; Rainer H Kohler; Mikael J Pittet; Ralph Weissleder
Journal:  Nat Biomed Eng       Date:  2018-05-21       Impact factor: 29.234

8.  Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers.

Authors:  F Zhang; N N Parayath; C I Ene; S B Stephan; A L Koehne; M E Coon; E C Holland; M T Stephan
Journal:  Nat Commun       Date:  2019-09-03       Impact factor: 14.919

Review 9.  Targeting macrophages: therapeutic approaches in cancer.

Authors:  Luca Cassetta; Jeffrey W Pollard
Journal:  Nat Rev Drug Discov       Date:  2018-10-26       Impact factor: 84.694

10.  PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.

Authors:  Sydney R Gordon; Roy L Maute; Ben W Dulken; Gregor Hutter; Benson M George; Melissa N McCracken; Rohit Gupta; Jonathan M Tsai; Rahul Sinha; Daniel Corey; Aaron M Ring; Andrew J Connolly; Irving L Weissman
Journal:  Nature       Date:  2017-05-17       Impact factor: 49.962
View more
  4 in total

1.  Activation of CD44 signaling in leader cells induced by tumor-associated macrophages drives collective detachment in luminal breast carcinomas.

Authors:  Feng Gao; Guoliang Zhang; Yiwen Liu; Yiqing He; Yumeng Sheng; Xiaodan Sun; Yan Du; Cuixia Yang
Journal:  Cell Death Dis       Date:  2022-06-09       Impact factor: 9.685

2.  Single-Cell Analyses of a Novel Mouse Urothelial Carcinoma Model Reveal a Role of Tumor-Associated Macrophages in Response to Anti-PD-1 Therapy.

Authors:  Dongbo Xu; Li Wang; Kyle Wieczorek; Yali Zhang; Zinian Wang; Jianmin Wang; Bo Xu; Prashant K Singh; Yanqing Wang; Xiaojing Zhang; Yue Wu; Gary J Smith; Kristopher Attwood; Yuesheng Zhang; David W Goodrich; Qiang Li
Journal:  Cancers (Basel)       Date:  2022-05-19       Impact factor: 6.575

3.  PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen.

Authors:  Mingyu Liu; Chong Wu; Shufeng Luo; Qiaomin Hua; Hai-Tian Chen; Yulan Weng; Junyu Xu; Huiling Lin; Lu Wang; Jinheng Li; Lan Zhu; Zhenhong Guo; Shi-Mei Zhuang; Tiebang Kang; Limin Zheng
Journal:  J Exp Med       Date:  2022-03-10       Impact factor: 17.579

4.  Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression.

Authors:  Ming Li; Hao Xu; Yanhua Qi; Ziwen Pan; Boyan Li; Zijie Gao; Rongrong Zhao; Hao Xue; Gang Li
Journal:  Oncogene       Date:  2022-09-09       Impact factor: 8.756
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.